Adicet Bio Inc (ACET NASDAQ) stock market data APIs
$0.8082
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Adicet Bio Inc Financial Data Overview
Price chart is built with
Anychart
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Prev. Close
0.8082
Open
0.81
High
0.828
Low
0.782
52 wk Range
0.4471-1.57
Market Cap
67 452 K
Shares Outstanding
83 254 K
EPS
-0.34
Beta
1.612
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Adicet Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adicet Bio Inc data using free add-ons & libraries
Get Adicet Bio Inc Fundamental Data
Adicet Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -119 623 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.3114
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adicet Bio Inc News
New
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet...
Adicet Bio (ACET) Q2 Loss Widens 3%
Key Points No revenue reported as clinical programs remain in precommercial stages. Workforce and cost reductions are expected to extend cash runway into the fourth quarter of 2026.These 10 stocks co...
Adicet Bio To Present At Jefferies Global Healthcare Conference; Webcast At 4:20 PM ET
(RTTNews) - Adicet Bio, Inc (ACET) will present in a fireside chat at the Jefferies Global Healthcare Conference, New York. The event is scheduled to begin at 4:20 PM ET on June 4, 2025. To access t...
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif. & BOSTON, January 25, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell thera...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
